N/A N=290 To Study Polycystic Ovary Syndrome in Taiwanese Women
Polycystic Ovary Syndrome · Metabolic Syndrome · Cardiovascular Disease
Primary: Total Testosterone — 1.5; 2.9 nmol/L — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=65 A Study of AZD4901 in Females With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Primary: Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7 — 1.118; 0.9729; 0.8804; 0.5364 Ratio
N/A N=21 Insulin and Polycystic Ovary Syndrome
PCOS
Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
N/A N=70 Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands
Polycystic Ovary Syndrome
Primary: Estradiol Level in Female Offspring — 18606; 6467 pg/ml — p=0.049
Phase 3 N=42 Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification — 10; 11; 11; 10…
Phase 3 N=92 Liver and Fat Regulation in Overweight Adolescent Girls
Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity
Primary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min
Phase 4 N=64 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
N/A N=67 Metabolic Syndrome in PCOS: Precursors and Interventions
Polycystic Ovary Syndrome · Metabolic Syndrome
Primary: Change in Low-density Lipoprotein (LDL) Levels Over the Study Period — -6; -9; -7 mg/dL
N/A N=41 Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Primary: 17-hydroxyprogesterone Responses to hCG in PCOS Women and Normal Controls — 1.3; 3; 1.1 ng/ml
N/A N=39 Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Percent Change of 17-OHP Levels From Baseline — 67; 140 percent change
Phase 2 N=149 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Polycystic Ovary Syndrome
Primary: Live Birth Rate — 13; 5; 12 participants — p=0.06
Phase 4 N=46 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
Polycystic Ovary Syndrome
Primary: Peripheral Insulin Sensitivity at Baseline and 6 Months. — 2.2; 2.1; 3.2; 2.0 mg/kg/min per uU/mL
N/A N=18 Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
Polycystic Ovary Syndrome · Obstructive Sleep Apnea
Primary: Estrogen Levels — 73.3; 69.9; 61.0 pg/ml
N/A N=90 Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Polycystic Ovary Syndrome · c Type Natriuretic Peptide · Menstrual Irregularity
Primary: Serum CNP Levels of PCOS and Healthy Participants — 110; 57 pg/ml — p=0.004
N/A N=14 Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Primary: Mu-opioid Binding Potential Measured in Left Nucleus Accumbens — 1.95; 1.65; 1.53 ratio — p=0.143
Phase 2 N=114 Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Change in Testosterone After 6 Months of Treatment — -2.1; -6.4 ng/dL — p=0.54
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
N/A N=7 Brain Metabolism in Polycystic Ovary Syndrome
Insulin Resistance
Primary: Global Brain Glucose PET Uptake — 34.9 umol/100 g/min
N/A N=25 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
Phase 2 N=23 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
Polycystic Ovary Syndrome (PCOS)
Primary: Lipid Content of PCOS Subcutaneous (SC) Abdominal Adipocytes Matured in Vitro. — 2.0; 5.6; 1.37; 3.8 fluorescence units/cell number — p=0.004
N/A N=61 Sex Steroids, Sleep, and Metabolic Dysfunction in Women
Polycystic Ovary Syndrome (PCOS) · Obstructive Sleep Apnea · Obesity
Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 2 N=118 Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Menstrual Cycle Responders — 7.7; 0; 0; 0 percentage of participants — p=0.300
Phase 2 N=28 Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI) — -0.008; 0.009 units on a scale — p=0.05
Phase 3 N=36 Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Polycystic Ovary Syndrome
Primary: Reduction in Abdominal Fat as Measured by Waist Circumference. — -3.9; -1.4 cm
Phase 4 N=51 Continuous Versus Cyclical OCP Use in PCOS
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
Phase 3 N=45 Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Number of Menses During the Six Month Study Period. — .42; .42; .75; .25 Number of menstrual cycles per month